S. Hrg. 118-750, Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a Federal Health Program Perspective (Senate Committee on Finance, 5 Dec 2023) (2023)

Government Record · U.S. Senate Committee on Finance · December 5, 2023

U.S. Senate Committee on Finance, 2023-12-05: Hearing record of the Senate Finance Committee's December 2023 examination of drug shortages, in which Chairman Wyden attributes shortages to consolidated generic purchasing driving prices below the level needed to fund reliable manufacturing.

The generic manufacturers that are awarded contracts by these middlemen do so by offering penny-on-the-dollar prices that mean they cannot invest in the capacity or equipment that is the key to actually making reliable, high-quality medications.

Senate hearing, HTML edition (unpaginated)

U.S. Senate Committee on Finance, 2023-12-05: Hearing record of the Senate Finance Committee's December 2023 examination of drug shortages, in which Chairman Wyden attributes shortages to consolidated generic purchasing driving prices below the level needed to fund reliable manufacturing. Funder/conflicts: n/a (legislative record; includes manufacturer, GPO, and academic testimony). Comparator: n/a. Also in the record: 'three companies control 90 percent of the pharmaceutical market', and witness testimony that 84 percent of shortages occur in generic drugs and 56 percent of shortage products have unit prices below one dollar. I did not verify the PDF variant loads; the HTML edition was opened and quoted. Study type: other.